Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial

被引:0
作者
Rondanelli, M. [1 ,2 ]
Gasparri, C. [3 ]
Petrangolini, G. [4 ]
Allegrini, P. [4 ]
Avenoso, D. [4 ]
Fazia, T. [5 ]
Bernardinelli, L. [5 ]
Peroni, G. [3 ]
Patelli, Z. [3 ]
Mansueto, F. [3 ]
Tartara, A. [3 ]
Cavioni, A. [3 ]
Riva, A. [4 ]
机构
[1] Univ Pavia, Dept Publ Hlth Expt & Forens Med, Pavia, Italy
[2] IRCCS Mondino Fdn, Pavia, Italy
[3] Univ Pavia, Azienda Serv Persona, Endocrinol & Nutr Unit, Ist Santa Margherita, Pavia, Italy
[4] Indena SpA, R&D Dept, Milan, Italy
[5] Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy
关键词
Berberine; Impaired fasting blood glucose; Phyto-someTM; Insulin; Body composition; RISK; ADULTS; KINASE;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
- OBJECTIVE: Berberine is a plant alkaloid known to exert positive metabolic effects. Human studies have confirmed its ability to improve the lipid and glycemic profile. This study aimed to evaluate the potential benefit of oral supplementation of Berberine PhytosomeTM (2 tablets/day, 550 mg/tablet) on the metabolic profile of subjects with impaired fasting blood glucose (IFG). PATIENTS AND METHODS: A total of 49 overweight subjects, 28 females and 21 males, were randomly assigned to either the supplemented group (n=24) or placebo (n=25). We considered glycemia as the primary endpoint and total cholesterol, high-density lipoprotein (HDL), total cholesterol/HLD, low-density lipoprotein (LDL), LDL/HDL, triglycerides, insulin, glycated hemoglobin, Homeostasis Model Assessment (HOMA), ApoA, ApoB, ApoB/ApoA, androgen suppression treatment (AST), alternative lengthening of telomeres (ALT), gamma-glutamyl transferase (GGT), creatinine, and body composition by Dual-energy X-ray Absorptiometry (DXA) as secondary endpoints. These parameters have been assessed at baseline, after 30 days, and after 60 days. RESULTS: After two months of treatment, through the use of linear mixed effect models, a statistically significant difference between supplemented and placebo groups was observed for glycemia [13=-0.2495% C.I. (-0.47;-0.06), p=0.004], total cholesterol [13=-0.25, 95% C.I. (-0.45;-0.04), p=0.05], total cholesterol/HDL [13=0.25, 95% C.I. (-0.43;-0.06), p=0.04], triglycerides [13=-0.14, 95% C.I. (-0.25;-0.02), p=0.05], insulin [13=-1.78, 95% C.I. (-2.87;-0.66), p=0.009], ApoB/ ApoA [13=-0.08, 95% C.I. (-0.13;-03), p=0.004], Visceral adipose tissue (VAT) [13=-91.50, 95% C.I. (-132.60;-48.19), p<0.0001] and fat mass [13=945.56, 95% C.I. (-1,424.42;-441.57), p=0.004]. CONCLUSIONS: The use of berberine had no adverse events, supporting its use as a natural alternative to pharmacological therapies in the case of IFG.
引用
收藏
页码:6718 / 6727
页数:10
相关论文
共 50 条
  • [1] Randomized, double-blind, placebo-controlled, clinical study on the effect of Diabetinol® on glycemic control of subjects with impaired fasting glucose
    Evans, Malkanthi
    Judy, William V.
    Wilson, Dale
    Rumberger, John A.
    Guthrie, Najla
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2015, 8 : 275 - 285
  • [2] Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial
    Panigrahi, Antarmayee
    Mohanty, Susant
    BMC ENDOCRINE DISORDERS, 2023, 23 (01)
  • [3] Antiobesity effect of Pediococcus pentosaceus LP28 on overweight subjects: a randomized, double-blind, placebo-controlled clinical trial
    Higashikawa, F.
    Noda, M.
    Awaya, T.
    Danshiitsoodol, N.
    Matoba, Y.
    Kumagai, T.
    Sugiyama, M.
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2016, 70 (05) : 582 - 587
  • [4] Effects of Pioglitazone on Bone in Postmenopausal Women With Impaired Fasting Glucose or Impaired Glucose Tolerance: A Randomized, Double-Blind, Placebo-Controlled Study
    Bone, Henry G.
    Lindsay, Robert
    McClung, Michael R.
    Perez, Alfonso T.
    Raanan, Marsha G.
    Spanheimer, Robert G.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (12) : 4691 - 4701
  • [5] JinqiJiangtang tablets for prediabetes: A randomized, double-blind and placebo-controlled clinical trial
    Wang, Hui
    Guo, Liping
    Shang, Hongcai
    Ren, Ming
    Wang, Xuemei
    Wang, Dehui
    Chen, Jianzong
    Li, Shuanglei
    Chen, Liming
    Wang, Yue
    Liu, Zhi
    Zhai, Jingbo
    Song, Yuzhen
    Cao, Hongbo
    Zhang, Junhua
    Liu, Chunxiang
    Sun, Xiao
    Huo, Da
    Mu, Wei
    Zhang, Li
    Zheng, Wenke
    Yan, Xiaoyan
    Yao, Chen
    SCIENTIFIC REPORTS, 2017, 7
  • [6] Effect of Barley on Postprandial Blood Glucose Response and Appetite in Healthy Individuals: A Randomized, Double-Blind, Placebo-Controlled Trial
    Kim, In-Sook
    Park, Soo-yeon
    Park, Min Ju
    Kim, Kyeong Jin
    Kim, Ji Yeon
    NUTRIENTS, 2024, 16 (22)
  • [7] The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial
    Li, Meijuan
    Liu, Ying
    Qiu, Yuying
    Zhang, Jing
    Zhang, Yonghui
    Zhao, Yongping
    Jia, Qiong
    Li, Jie
    PSYCHIATRY RESEARCH, 2021, 300
  • [8] Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial
    Antarmayee Panigrahi
    Susant Mohanty
    BMC Endocrine Disorders, 23
  • [9] Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial
    Zhao, Ying
    Yang, Yuan-Yuan
    Yang, Bao-Lin
    Du, Ya-Wei
    Ren, Da-Wei
    Zhou, Hong-Mei
    Wang, Jing
    Yang, Hui-Min
    Wang, Yao-Xian
    Zhang, Ying-Ying
    Wu, Sheng-Xian
    TRIALS, 2021, 22 (01)
  • [10] Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial
    Ying Zhao
    Yuan-Yuan Yang
    Bao-Lin Yang
    Ya-Wei Du
    Da-Wei Ren
    Hong-Mei Zhou
    Jing Wang
    Hui-Min Yang
    Yao-Xian Wang
    Ying-Ying Zhang
    Sheng-Xian Wu
    Trials, 22